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Abstract
The aim of this study was to investigate the potential of diffuse optical spectroscopy for monitoring of patients with
locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. Fifteen women receiving treatment for
LABC had the affected breast scanned before; 1 week, 4 weeks, and 8 weeks after treatment initiation; and before
surgery. Optical properties related to tissue microstructure and biochemical composition were obtained. Clinical and
pathologic tumor response was evaluated using whole-mount pathology after mastectomy. Patients who responded
to treatment demonstrated an initial increase followed by a drop in optical parameters measured in the whole breast,
whereas nonresponding patients demonstrated only a drop in the same parameters 1 week after treatment initia-
tion. Responding patients demonstrated a significant increase of 17% ± 7%, 8% ± 8%, 10% ± 7%, 11% ± 11%, and
16% ± 15% in deoxygenated hemoglobin, oxygenated hemoglobin, total hemoglobin concentrations, water percentage,
and tissueoptical index, 1week after treatment initiation, respectively. In contrast, nonrespondingpatients hadadecreaseof
14%± 9%, 18%± 7%, 17%± 7%, 29%± 7%, and 32%± 9% in their corresponding optical parameters. Deoxygenated
hemoglobin concentration (with 100% sensitivity, 83% specificity) andwater percentage (with 75% sensitivity, 100% spec-
ificity) were found to be the best predictors of treatment response at 1 week after starting treatment. The results of this
study suggest that optical parameters can be potentially used to predict and monitor patients’ responses to neoadjuvant
chemotherapy and can form a basis for the customization of treatments in which inefficacious treatments can be switched
to more efficacious therapies.
Translational Oncology (2012) 5, 238–246
Address all correspondence to: Dr Gregory J. Czarnota, Department of Radiation Oncology, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Room T2-167, Toronto,
Ontario, Canada M4N 3M5. E-mail: Gregory.Czarnota@sunnybrook.ca
1This project was funded by the Canadian Breast Cancer Foundation – Ontario Region through a research grant to G.J.C. and through a fellowship to O.F. Funding for this
work was also provided by the Terry Fox Foundation and Natural Sciences and Engineering Research Council of Canada. This research was also supported through a Cancer Care
Ontario Research Chair in experimental therapeutics and imaging awarded to G.J.C.
Received 23 December 2011; Revised 23 March 2012; Accepted 27 March 2012
DOI 10.1593/tlo.11346
www.transonc.com
Trans la t iona l Onco logy Volume 5 Number 4 August 2012 pp. 238–246 238
Copyright © 2012 Neoplasia Press, Inc.
1944-7124/12
Open access under CC BY-NC-ND license.
Introduction
Breast cancer is the most common malignancy for women in North
America. Approximately 5% to 15% of the estimated 200,000 new
cases diagnosed each year will present with locally advanced breast
cancer (LABC) [1,2]. Women with LABC have a very poor outcome
in both local and systemic recurrence (5-year survival rate of ∼50%)
[3]. Standard treatment for these patients is now usually neoadjuvant
systemic treatment (chemotherapy or, less frequently, endocrine
therapy) followed by surgery and radiotherapy [4]. However, LABC
treatment remains controversial because determining the optimal
treatment paradigm is fraught with uncertainties, both in terms of
the best treatment regimen to administer and its duration [2,5,6].
While complete pathologic response to neoadjuvant chemotherapy
has been demonstrated to correlate strongly with patient survival [7],
conventional clinical surrogates based on anatomic information such
as physical assessment, mammography, and standard clinical imaging
such as ultrasound suffer from an inability to objectively assess treatment
response early during the course of treatment [8].
To assess response to treatment, it is important to know the extent
of initial disease. In this regard, magnetic resonance imaging (MRI)
has shown promise as a staging tool that can accurately determine the
extent of cancer when compared with pathology specimens [9]. In par-
ticular, contrast-enhanced MRI has been proven to consistently detect
residual disease [10,11]. Another functional imaging technique, posi-
tron emission tomography (PET), has been reported to identify tumor
changes as early as 8 days after treatment [12]. However, both these
approaches can be costly. Furthermore, PET and MRI require the
use of exogenous contrast agents and use lengthy scan times that are
often unfeasible for ongoing monitoring of patients with late-stage
cancer. Hence, an alternative modality that can provide rapid and quan-
titative functional information about the extent of disease without the
requirement of exogenous contrast agents would be of considerable
value for evaluating responses to neoadjuvant therapy. It is important
to know if tumors and, by inference, dispersed cancer cells are respond-
ing to neoadjuvant chemotherapy because, if it is ineffective, it should
be changed to an effective therapy.
The need for a noninvasive and inexpensive imaging modality to
monitor treatment response has led to renewed interest in the poten-
tial of optical imaging. Diffuse optical spectroscopy (DOS) and diffuse
optical tomography (DOT) are noninvasive, nonionizing techniques
that use near-infrared light to rapidly provide quantitative spectral in-
formation (in tens of seconds) regarding the absorption and scattering
properties of tissue [13,14]. Typically, DOS uses a large spectral band-
width with a sparse number of spatial measurements, whereas DOT
is used to produce three-dimensional optical property maps at 1- to
3-mm resolution with lower spectral bandwidth. This relationship is
similar to that of magnetic resonance (MR) spectroscopy and MRI.
Measured optical properties can be converted to parameters related
to tissue microstructure and biochemical composition such as oxygen-
ated hemoglobin ([HbO2]), deoxygenated hemoglobin ([Hb]), total
hemoglobin concentration ([HbT] = [Hb] + [HbO2]), relative oxygen
saturation (StO2 = [HbO2] / [HbT]), relative oxygen desaturation (St =
[Hb] / [HbT]), water percentage (%H2O), lipid percentage (%Li),
scattering power (SP), scattering amplitude (SA), and tissue optical
index (TOI = [Hb](%H2O) / (%Li)). The TOI combines both func-
tional ([Hb] and%H2O) and structural (%Li and %H2O) information
for enhanced contrast, and this was used by previous investigators [15]
for DOS. This functional information is not readily available through
conventional structural imaging techniques. Because optical contrast
comes from intrinsic tissue components, the technique does not require
exogenous contrast agents, making it ideal for frequent, repeat moni-
toring. Furthermore, DOS technology is relatively inexpensive com-
pared with MRI and PET and provides functional information as a
potential complement to traditional structural imaging techniques such
as MRI [16] and ultrasound [17]. In normal breast tissue, optical in-
formation can be used to evaluate underlying physiological differences
as a result of age, body mass index, menopausal status, and fluctuations
in the menstrual cycle [18]. DOS has been used previously as a means
of differentiating between normal and malignant breast tissues [19].
Hypoxia, cellular proliferation, angiogenesis, and extracellular matrix
breakdown are biologic factors that have all been linked with cancer
and shown to directly influence the concentration of optical parameters
such as [HbT], %H2O, and %Li [19,20]. Because hypoxia and blood
flow are also correlated with chemotherapeutic resistance and degree of
response, both oxygen saturation and hemoglobin concentration may
be good indicators of tumor response [21,22].
Previous studies have suggested that DOS may provide clinically
useful information on whether a particular treatment regimen is suc-
cessful [15,23–26]. In a recent study, Soliman et al. [25] investigated
the potential of both DOS and DOT for treatment monitoring in
a study of 10 patients undergoing neoadjuvant chemotherapy. They
demonstrated that volume-weighted optical information such as Hb,
HbO2, and SP could provide an indication of response within 4 weeks
in patients undergoing various LABC neoadjuvant treatments. In the
work here, we present a different whole-breast approach to predict the
clinical response to neoadjuvant chemotherapy by monitoring changes
in optical parameters and relating them to clinical and postsurgical
pathologic outcome. We report the results of multiperiod study on
15 patients who received a variety of neoadjuvant treatment regimens.
We investigated the changes in 10 optical parameters (HbO2, Hb,
HbT, StO2, St, H2O, Li, SP, SA, and TOI) during the treatment of
patients who responded to the treatment and who did not. We also
compared results to a volume-weighted method indicating that the
whole-breast method can potentially detect changes earlier. The long-
term goal of this work was to use this method to customize chemo-
therapies to adapt to the patient’s response profile.
Materials and Methods
Study Protocol
The study included 15 patients with LABC treated at the Odette
Cancer Centre of the Sunnybrook Health Sciences Centre in accor-
dance with research ethics approval. These included the 10 patients
from the previous study using the volume-weighted method [25] in
addition to five new patients. Before the start of the study, signed
informed consent was obtained from all patients whose affected breasts
were scanned five times: before treatment; at 1 week, 4 weeks, and
8 weeks after initiation of treatment; and before surgery. Clinical exam-
inations were also carried out before each imaging session in addition to
regular patient visits. In accordance with institutional LABC care
policies, a 1.0-T MRI study (GE Healthcare, Waukesha, WI) using
a dedicated radiofrequency coil was performed only at baseline and
immediately before surgery as a measure of tumor size. Pathology was
examined after mastectomy on whole-mount [27] 5 × 7-in pathology
slides digitized using a confocal scanner (TISSUEscope; Huron Tech-
nologies, Waterloo, Ontario, Canada) at 2-μm resolution. Data on
grade, histologic subtype, size, and tumor response were recorded.
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Patients were categorized as having either a good pathologic response
or a minimal response. Good pathologic response was defined as be-
fore [25] and by others [28] as having a more than 50% reduction
in the tumor size in comparison to pretreatment size along with a re-
markable decrease in cellularity (<10% of cells appear to be viable and
invasive). Minimal pathologic response meant a small change in the
tumor size (<50% reduction or enlargement) compared to the pre-
treatment tumor size.
DOS/DOT Instrument
DOS images were collected using a commercial optical system
(SoftScan; ART, Inc, Montreal, Quebec, Canada) composed of four
individual pulsed semiconductor diode lasers (LDH-P; PicoQuant,
Berlin, Germany) operating at 690, 730, 780, and 830 nm, with a pulse
duration at full-width at half-maximum less than 150 picoseconds,
an average output of 0.5 mW when driven at 20 MHz (PDL 808;
PicoQuant), with an oscillator module to synchronize drivers. Photons
were collected by a mobile detector in a 1 cm-X constellation composed
of five optical fibers and detected by a photomultiplier (H7422P-50;
Hamamatsu, Bridgewater, NJ). A router processed the electrical pulse
from the photomultiplier before sending it to a time-correlated single-
photon counting board (SPC-130; Becker & Hickl, Berlin, Germany).
The count was time correlated with the synchronization signal provided
by the laser system driver.
Because the spectral range of the system does not extend to regions
where water and lipid concentrations are significant contributors to
absorption, estimation of the water (H2O) and lipid (Li) percentages
was based on the empirical linear relationship with the estimated
scattering power b, where b comes from μs′ = Aλ
−b. The scattering
amplitude A (arbitrary units) and the scattering power b (dimensionless)
are estimated from the relationship that approximates Mie scattering in
tissue in the near-infrared range, where μs′ is the scattering coefficient
(cm−1) and λ is the light’s wavelength (nm) [29]. The results of non-
clinical studies show that the sensitivity of the system allows detection
and quantification of absorption changes equivalent to less than 1 μmol
of blood [30].
Patients were scanned in a prone position and positioned into the
breast aperture under the guidance of a clinical research coordinator.
The scanning area encompassed the whole breast. To ensure consis-
tency, stabilizing plates were used to secure the breast in place and all
imaging parameters (i.e., angle, height, distance etc) at baseline were
recorded and used for all subsequent scans. A liquid optical compen-
sation medium (an oil-in-water emulsion that mimics average optical
properties of the human breast, with an average absorption coeffi-
cient of 0.04 cm−1 and an average effective scattering coefficient of
10 cm−1 at the four wavelengths used) was used in the breast aperture
to minimize light reflections at the breast interface that can degrade
image quality. The acquired data were reconstructed using commer-
cially available software associated with the SoftScan device, and
three-dimensional tomographic images were created from the optical
parameters with a 3-mm3 voxel size.
Data Analysis and Statistics
Mean measured values of [HbO2], [Hb], [HbT], StO2, St, %
H2O, %Li, SP, SA, and TOI in the entire breast were obtained
and integrated over the entire breast volume to calculate the integrated
optical index for each parameter. Volume-weighted parameters were
also calculated as before [25], as follows: The tumor was identified in
the pretreatment DOS images for each optical parameter. A volume of
interest (VOI) was created by choosing a threshold value that was
adjusted such that the VOI corresponded in size and location to the
tumor as known through other imaging and clinical examinations.
The threshold value was kept consistent at each time point for the
same optical parameter for each patient. Mean measured values in
the VOI were obtained and multiplied by the VOI volume to obtain
the volume-weighted parameters. These were limited to Hb, HbO2,
H2O, and SP as only those provided a volume easily identified and
consistent with tumor location. Percentage changes in the values from
baseline between clinical/pathologic responders and nonresponders at
each time for each of the optical parameters were compared indepen-
dently. Normality violations for each parameter were checked using the
Shapiro-Wilk test (GraphPad Prism 4;GraphPad Software, Inc, La Jolla,
CA). Depending on whether the changes were normally distributed or
not, statistical analysis using either a t test or a Mann-Whitney test (two-
sided, 95% confidence) was carried out to assess if patients showing
statistically significant changes in optical parameters at weeks 1 and 4
correlated to the patient population demonstrating treatment response
as defined by clinical criteria. In addition, a linear mixed model with
repeated-measures analysis was performed to determine the statistical
significance of each optical parameter.
Discriminant analysis (PASW Statistics 18; SPSS, Inc, Chicago, IL)
was used to determine which optical parameters discriminate between
responders and nonresponders at weeks 1 and 4. The changes in the
values of HbO2, Hb, HbT, StO2, St, H2O, Li, SP, SA, and TOI were
used as predictors in the analysis that aimed at providing the best
separation between the two groups. Sensitivity and specificity were
calculated to measure the performance of the classification test. Statis-
tics were also calculated on the volume-weighted data and compared
with whole-breast results.
Results
Patient and Tumor Characteristics
Patients’ physical, tumor, and treatment characteristics are sum-
marized in Table 1. Ten patients had all five scans as planned. The
mean patient age was 49 years (SD = 9 years, range = 36-64 years).
The average maximum tumor size was 7.9 cm (SD = 2.6 cm, range =
3.2-12 cm). Of the 15 subjects, 2 had lobular carcinoma, 10 were ER/
PR–positive, 7 were Her-2-neu–positive, and 9 were menstruating.
Two patients had tumor grade 1, one patient had tumor grade 3,
and the rest had tumor grade 2.
Most of the tumors had in situ components occupying between
5% and more than 90% of the overall tumor size. The remaining por-
tion of the tumor was invasive. Subjects had a variety of neoadjuvant
treatment plans. Seventy-five percent of patients had combined
anthracycline and taxane–based chemotherapy. Three patients had
combined chemoradiotherapy and one patient had sunitinib and
trastuzumab chemotherapy during the first three cycles. This was later
changed to docetaxel, trastuzumab, and pamidronate.
Clinical and Pathologic Assessment of Tumor Response
All studies were examined in the same manner by a board certified
pathologist (J.Z.) who interpreted all LABC pathology and determined
tumor response. Pathologic response results of all patients are presented
in Table 2. Patients 4, 10, and 12 had a significant reduction in the
tumor size, and they were categorized as good responders. Patients 6,
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8, 9, 11, and 13 were classified as good responders owing to the min-
imally invasive disease left. Although the remaining pathologic tumor
size was large in some cases, the appearance of decreased tumor cellu-
larity and rare groups of residual cells indicated a good response.
Patients 1, 3, 5, 7, 14, and 15 had a poor response. Their pathologic
tumor size slightly changed compared with their pretreatment MR
tumor size. Patient 2 was an exceptional case. PretreatmentMR showed
an invasive ductal carcinoma measuring 11.2 (AP) × 7.3 (ML) ×
8.3 (SI) cm. She was started on sunitinib/trastuzumab chemotherapy.
Three cycles later, her clinical condition worsened, with axillary
nodes increasing in size. Her chemotherapy was changed to docetaxel/
pamidronate/trastuzumab to which she responded with tumor decreas-
ing to 3 (ML) × 3 (SI) cm in size. She also developed bone metastases
and did not have a mastectomy.
DOS Assessment of Tumor Response
Three-dimensional functional tomographic images were created for
each patient. In Figure 1, representative DOS images and whole-
mount pathologic slides for a nonresponder and a responder acquired
at baseline, at week 1, at week 4, at week 8, and before surgery are
presented. A comparison of the previously used method (volume-
weighted) and the whole-breast method for HbO2 is presented in
Figure 2. Figure 3 demonstrates changes in four optical parameters
using the volume-weighted method. Table 3, A and B, presents values
as a percentage of the pretreatment scan for each of the optical param-
eters at 1 and 4 weeks of time, respectively. Volume-weighted param-
eters averaged for nonresponders and responders were significantly
different at 4 weeks for Hb (P = .005), H2O (P = .04), and SP
(P = .046). None of the four parameters studied were significantly
different at week 1 (P > .05). A repeated-measures analysis was also
done using a linear mixed model statistical analysis. The mean per-
cent change was −74.1% (SE = 4.7%) for Hb in responders versus
−18.7% (SE = 7.4) for Hb in nonresponders, exhibiting a statistically
significant difference (P < .001). The mean percent change was
−65.7% (SE = 7.3) for HbO2 in responders versus −29.2% (SE =
9.1) for HbO2 in nonresponders. This difference was also statistically
significant (P = .037). Both SP and H2O were found not to be statis-
tically significant (P > .05).
Figure 4 demonstrates the changes in 10 optical parameters between
responders and nonresponders divided into blood-related and other
parameters using the whole-breast method. The values as a percentage
of the pretreatment scan for each of the 10 optical parameters at 1 and
Table 2. Patients’ Pathologic Response Results.
Patient No. Pathologic Tumor Dimensions (AP × ML × SI) Notes Pathologic Response
1 1.8 × 4 × 4.5 Some response; very high nuclear grade with bizarre nuclei Poor
2 N/A Clinically good response with change in chemotherapy Initially poor then good
3 5.2 × 7 × 1.8 Large volume of tumor remaining Poor
4 1 × 1 × 0.7 Very small volume of tumor remaining Good
5 4.5 × 4 × 9 Large volume of residual invasive duct carcinoma Poor
6 2 × 7 × 3 Scattered foci of invasion; minimal tumor cellularity Good
7 8.9 × 7.7 × 3 High tumor cellularity Poor
8 2.5 × 4.8 × 3.6 Numerous small foci of invasive disease Good
9 2 × 6 × 3 Very small nests of cells remaining Good
10 1 × 0.9 × 0.7 Small volume of low-grade invasive duct carcinoma remaining Good
11 1.7 × 6 × 4.5 Rare groups of invasive cells remaining Good
12 0.2 × 0.2 Probable or definite response to presurgical therapy Good
13 3.5 × 2.3 × 1.3 Negligible invasive tumor remaining Good
14 2 × 2.9 × 1.5 and 2 × 1.1 × 1 Multifocal invasive duct carcinoma Poor
15 8 × 7.5 × 6 Large volume of low-grade invasive duct carcinoma remaining Poor
Notes were taken from pathology reports.
Table 1. Patients’ Characteristics.
Patient No. Age (years) Menopausal Status MR Tumor Dimensions
(AP × ML × SI; cm)
Histologic Diagnosis Grade ER/PR Her-2-neu Residual In Situ
Size (%)
Neoadjuvant Treatment
1 47 Premenopausal 5 × 4.5 × 4.5 Lobular 2 + − 70 Chemoradiotherapy
2 38 Premenopausal 11.2 × 7.3 × 8.3 Ductal 3 + + 0 Sunitinib, trastuzumab → docetaxel,
trastuzumab, pamidronate
3 54 Postmenopausal 6.1 × 7.8 × 3.3 Ductal 2 − − 5-10 Epirubicin, docetaxel
4 61 Postmenopausal 10 × 6 Ductal 2 − − 30 Chemoradiotherapy
5 56 Postmenopausal 11 × 6.3 × 5.5 Ductal 2 + − 5-10 Epirubicin, docetaxel
6 48 Premenopausal 7.8 × 4.6 × 5.5 Ductal 2 − + >80 AC + paclitaxel, trastuzumab
7 64 Postmenopausal 7.5 × 6.5 × 5.5 Ductal 2 + − 5-10 AC + paclitaxel, trastuzumab
8 45 Premenopausal 5.1 × 5.5 × 4.5 Ductal 2 + + >90 Chemoradiotherapy
9 47 Premenopausal 4.8 × 3.1 × 5.5 Ductal 2 + + 60 Docetaxel, carboplatinum, trastuzumab
10 57 Postmenopausal 10.2 × 7.2 × 6.8 Lobular 1 + + 5-10 FEC + docetaxel
11 43 Premenopausal 6.6 × 3.7 × 7.9 Ductal 2 + − 85 FEC + docetaxel
12 56 Postmenopausal 2.4 × 2.7 × 3.2 Ductal 2 − + 0 AC + paclitaxel, trastuzumab
13 49 Premenopausal 2.4 × 2.8 × 1.4 and
1.4 × 2.8 × 1.3
Ductal 2 − + >90 AC + paclitaxel, trastuzumab
14 38 Premenopausal 9 × 6.6 × 6 Ductal 2 + − 60 AC + paclitaxel
15 36 Premenopausal 12 × 11.6 × 8.9 Ductal 1 + − 20 AC + paclitaxel
AC indicates adriamycin and cytoxan; FEC, fluorouracil (5-FU), epirubicin and cyclophosphamide.
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4 weeks of time, respectively, are presented in Table 3, C and D. Non-
responders and responders were found to be significantly different at
1 week after treatment initiation for Hb (P = .04), HbO2 (P = .04),
HbT (P = .03), H2O (P = .01), and TOI (P = .02) parameters. How-
ever, only Hb (P = .002), HbT (P = .02), and St (P = .002) were found
to be significantly different at 4 weeks after initiation of treatment.
A linear mixed model with repeated-measures analysis was also
performed to determine the statistical significance of each optical
parameter. The mean percent change for Hb was 16.0% (SE =
5.5) in responders versus −21.5% (SE = 6.2) in nonresponders, where
it exhibited a statistically significant difference (P = .001). The mean
percent change for HbO2 was 2.8% (SE = 9.3) in responders versus
−28.0% (SE = 4.6) in nonresponders. This difference was also statis-
tically significant (P = .002). The mean percent change for H2O was
11% (SE = 9.0) in responders versus −29.3% (SE = 5.3) in non-
responders and was statistically significant (P = .001). The mean per-
cent change for St was 20.8% (SE = 2.5) in responders versus −11.7%
(SE = 7.2) in nonresponders and was also statistically significant (P =
.004). The mean percent change for HbT was 5.7% (SE = 7.7) in
responders versus −26.3% (SE = 4.7) in nonresponders and was
statistically significant (P = .002). The mean percent change for
SP was 1.7% (SE = 11.1) in responders versus −29.7% (SE = 5.0)
Figure 1. Transverse DOS images of the breast in a craniocaudal direction and whole-mount pathology. A representative nonresponder
is shown in A and a responder in B. The cross section for each time point was chosen at the center of the tumor. The color bar shows
oxyhemoglobin concentrations (μmol/L). The area of residual disease in the nonresponder and responder is identified by the black arrow.
Scale bars, 1 cm.
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in nonresponders and was also statistically significant (P = .001). The
mean percent change for TOI was 11.7% (SE = 12.5) in responders
versus −33.4% (SE = 6.8) in nonresponders. This difference was sta-
tistically significant as well (P < .001). Li, StO2, and SA were found
not to be statistically significant (P > .05).
Sensitivity and specificity for all parameters are also presented at
1 and 4 weeks’ time in Table 3. The best predictor of therapeutic
response of the volume-weighted method was Hb, particularly at
4 weeks’ time, where 100% for both sensitivity and specificity were
achieved. For the whole-breast method, both Hb (with 100% sensitiv-
ity, 83% specificity) and H2O (with 75% sensitivity, 100% specificity)
were found to give a good prediction of the ultimate clinical-pathologic
treatment response as early as 1 week after the start of treatment. At
4 weeks’ time, oxygen desaturation was found to be the best predictor
Figure 2. Comparison of the changes in oxyhemoglobin level between the nonresponder and the responder of Figure 1. Volume-weighted
method is shown in A and the whole-breast method is shown in B. The dots between week 8 and preoperative scans were not connected
because of the variation in the duration between the two scans for each patient. The preoperative scan varied depending on the operation
date for each patient.
Figure 3. Changes in deoxyhemoglobin, oxyhemoglobin, water, and scatter power measured in nonresponders and responders using the
volume-weighted method. The dots between week 8 and preoperative scans were not connected because of the variation in the duration
between the two scans for each patient. The preoperative scan varied depending on the operation date for each patient. Bars, SE.
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of the therapeutic response, with 100% for both sensitivity and speci-
ficity. Values seem to initially increase for responding patients.
Discussion
DOS is a noninvasive, nonionizing technique that uses near-infrared
light to rapidly provide functional and structural tissue information. It
does not require the use of exogenous markers, which makes it ideal
for repetitive scans during treatment monitoring. Previous studies
have demonstrated the feasibility of using DOS for monitoring treat-
ment in patients with LABC. A study on 11 patients receiving iden-
tical ariamycin/cytoxan (AC) treatments [15] indicated significant
reductions in tumor concentrations of HbT (27% ± 15%), HbO2
(33% ± 7%), and H2O (11% ± 15%) for responders when compared
with pretreatment concentrations within 1 week of the start of the treat-
ment. Nonresponders showed no significant changes for these pa-
rameters. A recent study [25] on 10 patients with greater diversity in
disease extent and treatment plans demonstrated large drops from base-
line of 68% ± 21%, 59% ± 20%, 51% ± 28%, and 53% ± 26% in Hb,
HbO2, H2O, and SP for responders 4 weeks after treatment initiation,
respectively. Small changes of only 18% ± 10%, 18% ± 21%, 15% ±
12%, and 13% ± 10% were observed in these parameters for non-
responding subjects 4 weeks after initiating treatment.
In the study here, we report the results of a larger cohort (n = 15)
verifying our earlier findings [25] but also investigating whole-breast
DOS effects. The overall trends of DOS parameters of interest
(Figure 3) were found to agree with our previous results [25]. After
4 weeks of treatment initiation, the mean Hb content was 32% ± 7%
for responders versus 80% ± 8% for nonresponders. The difference
was found to be statistically significant (P = .005). The mean percent
in HbO2 was 37% ± 11% for responders versus 70% ± 10% for non-
responders. The difference was found to only approach significance
(P = .1). The mean H2O content was 41% ± 11% for responders
versus 70% ± 10% for nonresponders (difference, P = .04), whereas
the mean SP content was 49% ± 9% for responders versus 84% ± 9%
for nonresponders (difference, P = .046). These results are encouraging
and provide further support to the potential of using DOS to monitor
treatment response in patients with LABC. As the tumor begins to
respond to treatment, the hemoglobin decreases, which may represent
a reduction in tumor oxygen consumption due to cell death. The
decrease in oxyhemoglobin is potentially associated with the diminish-
ment or the normalization of vascular supply or a reduction in pooled
hypoxic blood. Water and scatter power may decrease as a result of loss
of cellularity and diminished tumor edema [31].
The use of the whole-breast measurements to calculate the changes
in optical parameters (whole-breast method) leads to some interesting
findings. With the exception of patients 8 and 9 (discussed further in
the next paragraphs), DOS parameters (Hb, HbO2, HbT, H2O, SP,
and TOI) in responders exhibited a sharp increase during the first
few days of the treatment and then started to drop significantly with
treatment time as presented in Figure 4. In contrast, for nonresponders,
most of the changes in optical parameters were marked by a small initial
drop followed by a relatively slow diminishment. These whole-breast
changes were found to be statistically significant for Hb (P = .04),
HbO2 (P = .04), HbT (P = .03), H2O (P = .01), and TOI (P = .02)
Table 3. Discriminant Analysis.
Parameter Responders (Mean ± SE; %) Nonresponders (Mean ± SE; %) P Sensitivity (%) Specificity (%)
(A) Volume-weighted method at 1 week
Hb 82 ± 11 91 ± 8 0.6 83 75
HbO2 77 ± 12 95 ± 12 0.4 67 75
H2O 81 ± 14 85 ± 4 0.8 50 50
SP 86 ± 16 82 ± 5 0.9 50 50
(B) Volume-weighted method at 4 weeks
Hb 32 ± 7 80 ± 8 0.005* 100 100
HbO2 37 ± 11 70 ± 10 0.1 67 100
H2O 41 ± 11 82 ± 7 0.04* 83 100
SP 49 ± 9 84 ± 9 0.046* 83 100
(C) Whole-breast method at 1 week
Hb 117 ± 7 86 ± 9 0.04* 100 83
HbO2 108 ± 8 82 ± 7 0.04* 75 83
HbT 110 ± 7 83 ± 7 0.03* 75 83
H2O 111 ± 11 71 ± 7 0.01* 75 100
Li 107 ± 5 96 ± 10 0.6
StO2 105 ± 5 87 ± 8 0.1 75 67
St 117 ± 7 90 ± 12 0.1 75 83
SA 113 ± 6 96 ± 12 0.3 75 83
SP 103 ± 14 70 ± 8 0.06 75 83
TOI 116 ± 15 68 ± 9 0.02* 75 83
(D) Whole-breast method at 4 weeks
Hb 114 ± 6 72 ± 6 0.002* 100 80
HbO2 97 ± 13 66 ± 5 0.05 75 80
HbT 101 ± 10 68 ± 5 0.02* 75 80
H2O 99 ± 13 71 ± 7 0.09 75 100
Li 113 ± 11 85 ± 7 0.07 75 80
StO2 101 ± 14 79 ± 4 0.1
St 125 ± 7 86 ± 5 0.002* 100 100
SA 116 ± 15 83 ± 7 0.07 50 80
SP 92 ± 12 72 ± 4 0.1 50 80
TOI 99 ± 13 63 ± 9 0.05 100 80
For C, normality violation was found for the Li parameter, and Mann-Whitney was used to calculate the P value. The discriminant analysis was not applicable.
For D, normality violation was found for the StO2 parameter, and Mann-Whitney was used to calculate the P value. The discriminant analysis was not applicable.
*Significant result.
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as early as 1 week from the start of the treatment. Only changes in Hb,
HbT, and St were significant once the treatment reached the week 4
time point (Table 3). These findings suggest that changes in oxygen
consumption, vascularity, and tissue structure in the whole breast start
to occur as early as 1 week from the treatment initiation. At 4 weeks,
changes in oxygen consumption are reflected by changes in Hb, HbT,
and St, which provided a good separation between responders and non-
responders. The fast rise in HbO2 for responders during the first week
of the treatment is consistent with the recent findings reported by
Roblyer et al. [28]. In their study on 24 patients with LABC receiving
various treatment regimens, a significant flare in HbO2 was observed in
pathologic complete responding (n = 8) and partially responding tumors
(n = 11), opposed to nonresponders (n = 5), which exhibited a decrease
in HbO2 levels on day 1 after treatment initiation. They suggested that
such a oxyhemoglobin flare is likely due to a decrease in HbO2 con-
version to Hb as a result of a decrease in cellular metabolism and/or in-
creased tissue perfusion. As an alternative explanation, we suggest that
this may be related to the active metabolism associated with cell death.
This would require adenosine triphosphate (ATP) and glucose, which
would be provided by an increase in blood flow, leading to an edematous
and erythematous breast, often seen clinically in responders.
The trends observed in the changes of optical parameters in patients
8 and 9 were found to be similar to those of nonresponding patients.
These patients had negligible invasive tumor remaining and were rated
by the pathologist as good responders. However, in these patients, de-
spite the significant reduction in the size of the invasive disease, the overall
tumor size remained relatively large due an abundance of ductal carcinoma
in situ cells in the breast. In addition, they were the only two patients who
were both ER/PR– and Her-2-neu–positive and had carboplatinum or
radiation, both of which can create DNA cross-link lesions. In these sub-
jects, in addition to DOS measurements, patients’ characteristics such as
age, menopausal status, tumor composition and grade, ER/PR, Her-
2-neu, and neoadjuvant treatment may provide useful information to
classify therapy response. This will be investigated in the future once
more subjects with large in situ components are available.
The whole-breast method was found to be superior to the volume-
weighted method because it permitted the distinction between respond-
ers and nonresponders as early as 1 week after treatment initiation when
using deoxyhemoglobin (with 100% sensitivity, 83% specificity) and
percent water (with 75% sensitivity, 100% specificity) as predictors
of treatment response as shown in Table 3. At 4 weeks after start of
treatment, 100% sensitivity and 100% specificity for deoxyhemoglobin
and oxygen desaturation were achieved using the volume-weighted and
whole-breast methods, respectively. These results were generally consis-
tent and seemed to be independent of molecular drug mechanisms but
rather relate to, if ultimately, cell death in the tumor was or was not
induced. The different chemotherapy drugs used lead ultimately either
to apoptosis or to necrosis. We hypothesize that the results of the
Figure 4. Changes in DOS parameters measured in nonresponders and responders using the whole-breast method. (A) Blood-related
parameters: Hb, HbO2, HbT, StO2, and St. (B) Other parameters: Li, H2O, TOI, SA, and SP. The dots between week 8 and preoperative
scans were not connected because of the variation in the duration between the two scans for each patient. The preoperative scan varied
depending on the operation date for each patient. Bars, SE.
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whole-breast method may be due to concurrent changes in the optical
parameters measured within the tumor in addition to the surrounding
normal breast tissue over the treatment course as reported by previous
investigators [24] or potentially a metabolic flare.
The whole-breast method introduced in this work offers a potential ma-
jor advantage over previous methods [25,28]. The use of the whole-breast
measurements to calculate the changes in optical parameters does not re-
quire any knowledge of the tumor size and location and no tumor segmen-
tation and/or registration algorithms are needed to identify the tumor,
whichmakes this method simple and ideal for clinical settings. This method
may be dependent on tumor size but seemed to be appropriate for LABCs
because changes in optical parameters occur primarily in the tumor.
In conclusion, regardless of the treatment regimens, changes in the
DOS parameters correspondedwell to the clinical andwhole-mount path-
ologic response. This makes DOS potentially ideal for real-life scenarios
where treatment regimens are customized based on individual clinical
circumstances in women with LABC. A whole-breast method for data
analysis was introduced here in which a study on 15 patients showed that
five of the parameters were shown to be able to distinguish responders
from nonresponders as early as 1 week after treatment initiation. This
work indicates that it is possible to use this method to begin to customize
treatment regimens. It can also permit the objective rational of change
from ineffective therapies to effective ones early (within days to weeks)
as opposed to many months later, which can be potentially too late.
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